This Week in Cardiology-logo

This Week in Cardiology

Medical

This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.

Location:

United States

Description:

This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.

Language:

English


Episodes
Ask host to enable sharing for playback control

May 24 2024 This Week in Cardiology

5/24/2024
Clues in SCAF, a DOAC antidote trial, another negative lytic trial in stroke, JAMA changes to observational studies, and BP in stroke care are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. ARTESIA Substudy Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology https://www.medscape.com/viewarticle/998215 ARTESIA SubstudyNOAHhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303062ARTESIAhttps://www.nejm.org/doi/10.1056/NEJMoa2310234 II. DOAC Reversal ANNEXA-1 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2313040 III. Lytic Therapy in Acute Stroke Thrombolysis Offers No Benefit for Mild Stroke https://www.medscape.com/viewarticle/iv-thrombolysis-offers-no-benefit-mild-stroke-2024a10009p7 TEMPO-2 Trialhttps://doi.org/10.1016/S0140-6736(24)00921-8The Case Against Thrombolytic Therapy in Stroke IV. Observational Research JAMA Special Communicationhttps://jamanetwork.com/journals/jama/fullarticle/2818746JAMA editors notehttps://jamanetwork.com/journals/jama/fullarticle/2818747 V. Aggressive BP Control in Stroke Guidelines on Rapid BP Reduction in Acute Ischemic Stroke Challenged https://www.medscape.com/viewarticle/guidelines-rapid-bp-reduction-acute-ischemic-stroke-2024a10009pe TRUTH Trial https://doi.org/10.1016/S1474-4422(24)00177-7 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:28:56

Ask host to enable sharing for playback control

May 17 2024 This Week in Cardiology

5/17/2024
An Impella update, another TAVI vs SAVR trial, two studies on angina and PCI, another null substudy from REVIVED-BCIS, and semaglutide are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Impella Update CHRIP BCIS 3 https://classic.clinicaltrials.gov/ct2/show/NCT05003817Danger-Shock Podcast https://www.medscape.com/viewarticle/1000675 II. TAVI vs SAVR Notion 2 TrialEHJ https://doi.org/10.1093/eurheartj/ehae331DEDICATE-DZHK6 III. Angina and PCI Orbita 2 Sub-analysisOrbita Star https://www.jacc.org/doi/10.1016/j.jacc.2024.04.001 IV. Complete Revascularization Main REVIVED trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206606JACC Substudy https://www.jacc.org/doi/10.1016/j.jacc.2024.04.043 V. Semaglutide Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT Data https://www.medscape.com/viewarticle/semaglutide-cv-benefits-irrespective-weight-loss-4-year-2024a100095z Nature Med substudy https://www.nature.com/articles/s41591-024-02996-7SELECT Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:29:51

Ask host to enable sharing for playback control

May 10 2024 This Week in Cardiology

5/10/2024
Inclisiran, sodium-channel blocker safety, analytic flexibility, the work-up of patients with HF, and BP in older patients are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Inclisiran Update ORION 4https://classic.clinicaltrials.gov/ct2/show/NCT03705234 II. Sodium-Channel AADs UPenn Paperhttps://doi.org/10.1016/j.jacep.2024.01.021Three Questions Ehttps://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381EAST Post-hoc Reviewhttps://doi.org/10.1093/europace/euae121 III. Analytic Flexibility Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat https://www.medscape.com/viewarticle/red-meat-healthy-multiverse-analysis-has-lessons-beyond-meat-2024a10008qv Specification Curve Analysis of Red Meat Datahttps://doi.org/10.1016/j.jclinepi.2024.111278 IV. The Work-up of Patients With HF Durstenfeld and colleagues, UCSFhttps://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010800REVIVED BCIS2 https://www.nejm.org/doi/full/10.1056/NEJMoa2206606 V. BP Therapy in Older Patients Haring and colleagues; Women’s Health Initiative BP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067302SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:31:56

Ask host to enable sharing for playback control

May 03 2024 This Week in Cardiology

5/3/2024
The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. TAVR vs SAVR TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis https://www.medscape.com/viewarticle/tavi-comparable-savr-lower-risk-aortic-stenosis-2024a100074o?form=fpf DEDICATE https://www.nejm.org/doi/full/10.1056/NEJMoa2400685Partner 3 https://www.nejm.org/doi/full/10.1056/NEJMoa1814052Evolut Low Risk https://www.nejm.org/doi/full/10.1056/NEJMoa1816885Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516 II. Renal Denervation Alcohol-Mediated Renal Denervation Promising in Hypertension https://www.medscape.com/viewarticle/alcohol-mediated-renal-denervation-promising-hypertension-2024a10007eg TARGET 1 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069291 III. Inclisiran Earlier Inclisiran Gives Better Long-Term LDL Reductions https://www.medscape.com/viewarticle/earlier-inclisiran-gives-better-long-term-ldl-reductions-2024a10007d6 VICTORIAN INITIATE Trialhttps://www.jacc.org/doi/10.1016/j.jacc.2024.03.382 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:20:53

Ask host to enable sharing for playback control

Apr 26 2024 This Week in Cardiology

4/26/2024
A listener defends colored boxes in guidelines; mysteries of non-culprit coronary lesions during PCI, and of AF ablation; and surrogate markers are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Mystery of What to Do in the Cath Lab after Fixing the Culprit Lesion – The FULL REVASC Trial Complete Revascularization Not Superior to Culprit-Only PCI After MI https://www.medscape.com/viewarticle/complete-revascularization-not-superior-culprit-only-pci-2024a10007ik FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149FIRE Trial https://www.nejm.org/doi/10.1056/NEJMoa2300468COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775Cohen Tweet on FULL REVASC https://x.com/djc795/status/1781361606238085532 II. AF Ablation Mysteries New Expert Consensus on Ablation Strategies for AF https://www.medscape.com/viewarticle/new-expert-consensus-ablation-strategies-af-2024a1000851 Bern Study of Remapping https://doi.org/10.1016/j.jacep.2024.02.026Natural History of SCAF https://doi.org/10.1016/j.jacc.2019.09.050Liverpool Study: Thermal PV Isolation in Persistent AF https://doi.org/10.1016/j.hrthm.2024.04.061 III. Surrogate Markers JAMA: Surrugate Markers and Clinical Outcomes https://jamanetwork.com/journals/jama/fullarticle/2817850BP Surrogate Meta-analysis https://doi.org/10.1016/S0140-6736(21)00590-0JAMA:Nonfatal MI as Surrogate for Mortality https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:28:20

Ask host to enable sharing for playback control

Apr 19 2024 This Week in Cardiology

4/19/2024
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. TACT 2 Chelation Therapy Provides No Benefit Post-MI https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5 Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src= JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655 II. Interatrial Shunts for HF No Net HF Benefit for Interarterial Shunt Device https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2 III. Triglyceride Lowering Early Olezarsen Results Show 50% Reduction in Triglycerides https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz Is It Time to Stop Treating High Triglycerides? https://www.medscape.com/viewarticle/990126 NEJMhttps://www.nejm.org/doi/full/10.1056/NEJMoa2402309 Substantial Triglyceride Reduction With Plozasiran https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm JAMA Cardiologyhttps://jamanetwork.com/journals/jamacardiology/article-abstract/2817469 IV. Diltiazem and Factor Xa inhibitors JAMA Vanderbilt University Paperhttps://jamanetwork.com/journals/jama/fullarticle/2817546 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:28:46

Ask host to enable sharing for playback control

Apr 12 2024 This Week in Cardiology

4/12/2024
ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. DanGer-Shock Trial Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659 Published DanGer Shock Study https://www.nejm.org/doi/full/10.1056/NEJMoa2312572JAMA Research letterhttps://jamanetwork.com/journals/jama/article-abstract/2817457 II. REDUCE-AMI Trial New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8 Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663 REDUCE-AMI paperhttps://www.nejm.org/doi/full/10.1056/NEJMoa2401479Meta-analysis: Beta Blockers for MIhttps://doi.org/10.1016/j.amjmed.2014.05.032 III. PREVENT Trial Preventive PCI for Vulnerable Plaques Reduces Cardiac Events https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc Preventive Coronary Stents: Not There Yet https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr PREVENThttps://doi.org/10.1016/S0140-6736(24)00413-6 IV. EMPACT MI trial of Empagliflozin in the Post-MI setting Empagliflozin Fails to Reduce Events After Acute MI https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care https://www.medscape.com/viewarticle/1000684EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508Kaul thread https://x.com/kaulcsmc/status/1776611935842165029Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:29:08

Ask host to enable sharing for playback control

Apr 05 2024 This Week in Cardiology

4/5/2024
Statins and diabetes, AAD in patients with heart disease, tricuspid valve interventions, and an ACC preview are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Statins and Diabetes Meta-analysis in Lancet-Diabetes https://doi.org/10.1016/S2213-8587(24)00040-8Editorial https://doi.org/10.1016/S2213-8587(24)00059-7NEJM Paper on Gene Variants and DM https://www.nejm.org/doi/full/10.1056/nejmoa1604304JAMA Paper on Gene Variants and DM https://jamanetwork.com/journals/jama/fullarticle/2565289 II. Anti-arrhythmic Drugs in Patients With Serious Heart Disease UPenn Paper on AADs for PVC Suppression https://doi.org/10.1016/j.jacep.2024.01.021Three Questions for Evidence-Based Cardiac EP https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381CAST trial https://www.nejm.org/doi/full/10.1056/NEJM199103213241201 III. Tricuspid Valve Interventions FDA Clears TriClip for Tricuspid Regurgitation https://www.medscape.com/viewarticle/fda-clears-triclip-tricuspid-regurgitation-2024a100068o FDA Panel in Favor of TriClip for Tricuspid Regurgitation https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n Slides for Trisend IITRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 IV. ACC Preview Mandrola's Three Trials to Look for at the 2024 American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/1000613 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:26:43

Ask host to enable sharing for playback control

Mar 29, 2024 This Week in Cardiology Podcast

3/29/2024
Intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, the importance of the ECG, and industry conflicts are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Intermittent Fasting No, Intermittent Fasting Won't Kill You https://www.medscape.com/viewarticle/1000544 NEJM Paper on Time-Restricted Eating https://www.nejm.org/doi/full/10.1056/NEJMoa2114833JAMA TREAT Clinical Trialhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095 II. Stroke Prevention with OAC Shah Meta analysis of Vitamin K Agonists in AFhttps://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010269 III. Heterogenous Treatment Effects in Trials Pivotal CV Trials May Not Apply to Complex Patients https://www.medscape.com/viewarticle/989129 Analysis of 8 Trials of Multimorbidity and Treatment Responsehttps://doi.org/10.1016/j.amjmed.2024.01.028 IV. Frailty and HF Circulation Outcomeshttps://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010416 V. ECG in LBBB JAMA Cardiology:Revised Definition of LBBB https://jamanetwork.com/journals/jamacardiology/fullarticle/2816973 VI. Industry Payments to Doctors JAMA:Payments to US Physicians by Specialtyhttps://jamanetwork.com/journals/jama/fullarticle/2816900 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:28:36

Ask host to enable sharing for playback control

Mar 22 2024 This Week in Cardiology

3/22/2024
p>Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Denmark Notes II. FDA approval of Semaglutide FDA Approves Semaglutide for Cardiovascular Risk Reduction https://www.medscape.com/viewarticle/fda-approves-semaglutide-cardiovascular-risk-reduction-2024a10004ix Select Trial III. PPG Monitor Accuracy Research Letter https://doi.org/10.1016/j.jacc.2024.01.024 IV. AAD and Bradycardia Anti-arrhythmic Drugs Linked to Bradycardia in Patients With AF https://www.medscape.com/viewarticle/anti-arrhythmic-drugs-linked-bradycardia-patients-af-2024a10004vw JACCpaper on AAD Adverse Effects https://doi.org/10.1016/j.jacc.2024.01.013 V. Finding Signals in RCTs JAMApaper on Treatment Effects of Oxygen TargetsDANISH trialhttps://www.nejm.org/doi/full/10.1056/nejmoa1608029LAFFLIN et al. Scoring System to Assess Generalizability of Trial Results https://doi.org/10.1177/2047487318815967 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:26:19

Ask host to enable sharing for playback control

Mar 08 2024 This Week in Cardiology

3/8/2024
Plastics and heart disease, MINT trial letters-to-the-editor and Bayes theorem, and Brugada syndrome are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Plastics and Heart Disease Plastic Particles in Carotid Plaques Linked to CV Events https://www.medscape.com/viewarticle/plastic-particles-carotid-plaques-linked-cv-events-2024a10004ge Plastics and ASCVD Study https://www.nejm.org/doi/full/10.1056/NEJMoa2309822Review https://www.nejm.org/doi/full/10.1056/NEJMra2300476Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2400683 II. MINT trial LTE and Bayes Theorem In MI With Anemia, Results May Favor Liberal Transfusion: MINT https://www.medscape.com/viewarticle/998376 The MINT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307983Letter-to-the-Editor https://www.nejm.org/doi/full/10.1056/NEJMc2400982Likelihood Ratio https://www.cebm.ox.ac.uk/resources/ebm-tools/likelihood-ratios III. Brugada Syndrome The EHJ paper: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae133/7623123 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:26:53

Ask host to enable sharing for playback control

Mar 1 2024 This Week in Cardiology

3/1/2024
The Western AF meeting, aspirin, cannabis use, LVEF in athletes, and shared decision making before ICD implantation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. ASA in Primary Prevention Campbell Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065420Swedish Observational study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028321ASPREE https://www.nejm.org/doi/full/10.1056/NEJMoa1805819 II. Cannabis Cannabis Use Tied to Increased Cardiovascular Risk https://www.medscape.com/viewarticle/cannabis-use-tied-increased-cardiovascular-risk-2024a10003yr It Sure Looks Like Cannabis Is Bad for the Heart, Doesn’t It? https://www.medscape.com/viewarticle/1000250 Journal of the AHAObservational Study https://www.ahajournals.org/doi/full/10.1161/JAHA.123.030178 III. Low EF in Athletes Reduced Ejection Fraction in Elite Endurance Athletes: Clinical and Genetic Overlap With Dilated Cardiomyopathy https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.063777 IV. ICDs and Shared Decision-Making Association of a Medicare Mandate for Shared Decision-Making With Cardiac Device Utilization https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2815017 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:28:35

Ask host to enable sharing for playback control

Feb 23 2024 This Week in Cardiology

2/23/2024
Reading incidental CAC on chest CT scans, exercise benefits in women vs men, PCI with or without imaging, and trial non-reporting are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Incidental CAC on Chest CT Incidental CACTweetWhen Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry https://doi.org/10.1016/j.jcmg.2023.03.008 II. Exercise Health Gains of Exercise Greater in Women? https://www.medscape.com/viewarticle/health-gains-exercise-greater-women-2024a10003fv Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular Mortality III. PCI With or Without Imaging Intravascular Imaging in PCI: Time for a Guideline Update? https://www.medscape.com/viewarticle/995677 Meta-analysis paper Lancet https://doi.org/10.1016/S0140-6736(23)02454-6Imaging uptake paper https://doi.org/10.1093/eurheartj/ehad430 IV. Trial Non-reporting The Ghost Research Haunting Nordic Medical Trials https://www.medscape.com/viewarticle/ghost-research-haunting-nordic-medical-trials-2024a10003gz Manuscript/preprint https://www.medrxiv.org/content/10.1101/2024.02.04.24301363v1#T10Nissen (Rosiglitazone) https://www.nejm.org/doi/10.1056/NEJMoa072761 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:28:49

Ask host to enable sharing for playback control

Feb 16 2024 This Week in Cardiology

2/16/2024
An update in trial interpretation, CI, and P-values; percutaneous tricuspid Interventions; and news on HDL and humility in Medicine are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Evidence of Absence Is not Absence of Evidence Feb 09, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1000101 ARCADIA Trial https://jamanetwork.com/journals/jama/fullarticle/2814933FOURIER Trial https://www.nejm.org/doi/full/10.1056/nejmoa1615664Sample Size Calculator https://clincalc.com/stats/samplesize.aspx II. Tricuspid Valve Interventions FDA OKs First Transcatheter Tricuspid Valve Replacement https://www.medscape.com/viewarticle/fda-oks-first-transcatheter-tricuspid-valve-replacement-2024a10002dq FDA Panel in Favor of TriClip for Tricuspid Regurgitation https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n Cardiothoracic Surgical Trials Network Study https://www.nejm.org/doi/full/10.1056/NEJMoa2115961TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525KAUL Tweet on ATTR Cardiomyopathy https://twitter.com/kaulcsmc/status/1753552603534016622?s=20APOLLO B trial https://www.nejm.org/doi/full/10.1056/NEJMoa2300757Al-Lamee Tweet on Sham Controls https://x.com/rallamee/status/1758236588570562736 III. HDL Cholesterol Rationale paper — AEGIS https://doi.org/10.1016/j.ahj.2020.10.052Press Release AEGIS II https://www.prnewswire.com/news-releases/csl-announces-top-line-results-from-the-phase-3-aegis-ii-trial-evaluating-the-efficacy-and-safety-of-csl112-apolipoprotein-a-i-human-302059156.html You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:23:59

Ask host to enable sharing for playback control

Feb 09 2024 This Week in Cardiology

2/9/2024
Beta-blocker withdrawal in HFpEF, the ARCADIA trial, food as medicine, and bariatric surgery are the topics John Mandrola, MD, discusses in today’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. HFpEF and Heart Rate PRESERVE HF Substudy https://jamanetwork.com/journals/jamacardiology/fullarticle/2814596PRESERVE HF Original https://doi.org/10.1016/j.jacc.2021.08.073 II. ARCADIA trial ARCADIA Main Paper: Apixaban vs ASA https://jamanetwork.com/journals/jama/fullarticle/2814933KAMEL’s AF and Stroke Paper 10.1161/STROKEAHA.115.012004AVERROES Substudy -- 10.1016/S1474-4422(12)70017-0 III. Food as Medicine Food-As-Medicine Trial results: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2812982NPR Story https://www.npr.org/sections/thesalt/2017/05/08/526952657/fresh-food-by-prescription-this-health-care-firm-is-trimming-costs-and-waistline IV. Bariatric Surgery Weight Loss Surgery Yields Long-Term BP Control in Obesity https://www.medscape.com/viewarticle/weight-loss-surgery-yields-long-term-bp-control-obesity-2024a10002le Gateway RCT https://doi.org/10.1016/j.jacc.2023.11.032 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:25:50

Ask host to enable sharing for playback control

Feb 02 2024 This Week in Cardiology

2/2/2024
FDA approves PFA for AF ablation, flawed comparisons of TEER vs MV surgery and PCI vs CABG, and cardiologists struggling with board exams are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. PFA FDA Okays Boston Scientific PFA System for Paroxysmal AF https://www.medscape.com/viewarticle/fda-okays-boston-scientific-pfa-system-paroxysmal-af-2024a1000275 Pulsed-Field Ablation for AF: The Promise and the Reality https://www.medscape.com/viewarticle/995675 ADVENT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307291EU-PORIA Registry https://doi.org/10.1093/europace/euad185Tomlinson/Mandrola Editorial https://www.jacc.org/doi/10.1016/j.jacc.2020.07.032 II. TEER vs MV Surgery EHJ Paper https://doi.org/10.1093/eurheartj/ehae046 III. ISCHEMIA Post-Hoc Studies JACC Post-Hoc ISCHEMIA Trialhttps://doi.org/10.1016/j.jacc.2023.11.002Main ISCHEMIA paper https://www.nejm.org/doi/full/10.1056/nejmoa1915922FAME 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2112299 IV. Board Exams More Cardiologists Failing the Boards, Why and How to Fix? https://www.medscape.com/viewarticle/more-cardiologists-failing-boards-why-and-how-fix-2024a10001oi You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:27:45

Ask host to enable sharing for playback control

Jan 26 2024 This Week in Cardiology

1/26/2024
LAAO, more evidence that stable CAD is stable, CRT benefit over the long-term, and AF monitoring after stroke are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. LAAO This Week in Cardiology Podcast, Dec 15, 2023 https://www.medscape.com/viewarticle/999282 European Heart Journal paper https://academic.oup.com/eurheartj/article/45/3/214/7471675LAAOS 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2101897 II. CAD after Transcatheter Aortic Valve Implantation Cleveland Clinic Observational study https://doi.org/10.1093/eurheartj/ehae019ACTIVATION trial https://doi.org/10.1016/j.jcin.2021.06.041 III. Cardiac Resynchronization Therapy Original RAFT 2010 https://www.nejm.org/doi/full/10.1056/nejmoa1009540Long-term RAFT https://www.nejm.org/doi/full/10.1056/NEJMoa2304542Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2312419 IV. AF Monitoring After Stroke Japanese Observational Study https://www.ahajournals.org/doi/10.1161/JAHA.123.031508ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062LOOP substudy https://jamanetwork.com/journals/jamaneurology/fullarticle/2795865CRYSTAL AF https://www.nejm.org/doi/full/10.1056/nejmoa1313600 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:29:35

Ask host to enable sharing for playback control

Jan 19 2024 This Week in Cardiology

1/19/2024
Listener feedback on antiplatelet therapy after PCI, bempedoic acid, off-Label PFO Closure, and palliative care are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback on Antiplatelet Therapy After PCI Long-term Clopidogrel Has Advantages After Coronary Stenting https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8 Host Exam Study; Extended FU of Host-Exam https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062770 II. Bempedoic Acid This Week in Cardiology July 7, 2023 https://www.medscape.com/viewarticle/994089 NEJM:Bempedoic Acid and CV Outcomes JAMA:Primary Prevention Analysis https://jamanetwork.com/journals/jama/fullarticle/2806646 JAMA-Cardiology:Total Events Analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2813647/ III. Off-Label PFO Closure Circulation Outcomes Paperhttps://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010200 IV. Palliative Care JAMA: Palliative Care Consultation You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:29:51

Ask host to enable sharing for playback control

Jan 12 2024 This Week in Cardiology

1/12/2024
GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. GLP-1s and Obesity, BaroStim Neo Revisited FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726 II. ATTR Cardiomyopathy ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434 Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915 ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689 III. Clopidogrel vs ASA Years After PCI Long-term Clopidogrel Has Advantages After Coronary Stenting https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8 Stop DAPT Original Trial STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013 Network Meta-analysis of P2Y-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009 IV. Statin Use Statin Use Remains Low for At-Risk Patients https://www.medscape.com/viewarticle/999043 Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Duration:00:26:36

Ask host to enable sharing for playback control

Jan 05 2024 This Week in Cardiology

1/5/2024
Neuro-modulation in HF, private equity owned hospitals, HCM, SCD and ICD re-evaluated, and peer review are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Neuromodulation for HFrEF FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx BeAT HF trial https://doi.org/10.1016/j.jacc.2020.05.015 II. Private Equity Takeover of US Hospitals Hospital Adverse Events Rise After Private Equity Acquisition https://www.medscape.com/viewarticle/hospital-adverse-events-rise-after-private-equity-2023a1000wya Changes in Hospital Adverse Events and Patient Outcomes Associated With Private Equity Acquisition: https://jamanetwork.com/journals/jama/article-abstract/2813379 RSS audio: https://bi.medscape.com/pi/editorial/studio/audio/2024/core/999557.mp3 III. Hypertrophic Cardiomyopathy Positive Topline Results for SEQUOIA-HCM Trial in OHCM https://www.medscape.com/viewarticle/positive-topline-results-sequoia-hcm-trial-ohcm-2023a1000wu9 IV. The ICD gets a ReLook Study to Examine Routine ICD Implantation Post Heart Attack https://www.medscape.com/viewarticle/study-examine-routine-icd-implantation-post-heart-attack-2023a1000wmd PROFID Site https://profid-project.eu/profid-ehra-trial/ Declining Risk of Sudden Death in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 V. Peer Review Prevalence of Short Peer Reviews in 3 Leading General Medical Journals -- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2812883 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.n

Duration:00:25:03